Akanda

Akanda Capital Intensity

The Capital Intensity Ratio of Akanda (AKAN) as of Oct 27, 2026 is 2,400.68 %. In the previous year, Capital Intensity Ratio was 945.91 % — a change of 153.80% (higher).

Capital Intensity

2,400.68 %

YoY

153.80%

Last updated:

Capital Intensity Ratio of Akanda is 2025 2,400.68 % . Capital Intensity Ratio of Akanda was 2024 945.91 % . It decreases by 153.80% higher compared to the previous year.

The Akanda Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2020
207,314.11 USD
Jan 1, 2021
19,420.25 USD
Jan 1, 2022
1,488.61 USD
Jan 1, 2023
409.25 USD
Jan 1, 2024
945.91 USD
Jan 1, 2025
2,400.68 USD
The Akanda Capital Intensity history
YEARCapital IntensityYoY
2,400.68 %+153.80%
945.91 %+131.13%
409.25 %-72.51%
1,488.61 %-92.33%
19,420.25 %-90.63%
207,314.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Capital Intensity Ratio of Akanda is 2,400.68 % in 2025.

Capital Intensity Ratio of Akanda changed from 945.91 % to 2,400.68 %, representing a 153.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Akanda since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Akanda with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Akanda

All Key Metrics — Akanda